Coronavirus India Live News Update: India reports 9,283 new cases; Covaxin shows 50% effectiveness against symptomatic COVID-19 in real-world assessment, says Lancet study
Researchers noted that the Delta variant was the dominant strain in India during the study period, accounting for approximately 80 per cent of all confirmed COVID-19 cases. (PTI Photo)
Coronavirus Variants and Vaccinations, Coronavirus Active Cases in India Today, November 24: Two doses of Covaxin are 50 per cent effective against symptomatic COVID-19, according to the first real-world assessment of India’s indigenous coronavirus vaccine published in The Lancet Infectious Diseases journal. The results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns.
The study also found that the vaccine effectiveness against symptomatic COVID-19 after two doses of Covaxin with the second dose administered 14 or more days before undergoing RT-PCR testing was 50 per cent. The adjusted vaccine effectiveness of the first dose, estimated after seven and 21 days, was low, which is consistent with the performance of other preventives against the Delta variant, they said.
Here are the latest and verified updates related to the Coronavirus pandemic from India and around the globe:
For all the latest Life Style News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
